Treating osteoarthritis pain: mechanisms of action of acetaminophen, nonsteroidal anti-inflammatory drugs, opioids, and nerve growth factor antibodies

References

• Cross M, Smith E, Hoy D, et al. The global burden of hip and knee osteoarthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis. 2014;73(7):1323–1330.
   PubMed Web of Science ®Google Scholar
• Cao P, Li Y, Tang Y, et al. Pharmacotherapy for knee osteoarthritis: current and emerging therapies. Expert Opin Pharmacother. 2020;21(7):797–809.
   PubMed Web of Science ®Google Scholar
• Zhang W, Robertson WB, Zhao J, et al. Emerging trend in the pharmacotherapy of osteoarthritis. Front Endocrinol (Lausanne). 2019;10:431.
   PubMed Web of Science ®Google Scholar
• Jordan KM, Arden NK, Doherty M, et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis. 2003;62(12):1145–1155.
   PubMed Web of Science ®Google Scholar
• Kolasinski SL, Neogi T, Hochberg MC, et al. 2019 American College of Rheumatology/Arthritis Foundation guideline for the management of osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken). 2020;72(2):149–162.
   PubMed Web of Science ®Google Scholar
• Zhang W, Doherty M, Arden N, et al. EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2005;64(5):669–681.
   PubMed Web of Science ®Google Scholar
• Spitaels D, Mamouris P, Vaes B, et al. Epidemiology of knee osteoarthritis in general practice: a registry-based study. BMJ Open. 2020;10(1):e031734.
   PubMed Web of Science ®Google Scholar
• Birtwhistle R, Morkem R, Peat G, et al. Prevalence and management of osteoarthritis in primary care: an epidemiologic cohort study from the Canadian Primary Care Sentinel Surveillance Network. CMAJ Open. 2015;3(3):E270–275.
   PubMedGoogle Scholar
• Zeng C, Zhang W, Doherty M, et al. Initial analgesic prescriptions for osteoarthritis in the United Kingdom, 2000-2016. Rheumatology (Oxford). 2021;60(1):147–159.
   PubMed Web of Science ®Google Scholar
• Trentalange M, Runels T, Bean A, et al. Analgesic prescribing trends in a national sample of older veterans with osteoarthritis: 2012-2017. Pain. 2019;160(6):1319–1326.
   PubMed Web of Science ®Google Scholar
• Akazawa M, Mimura W, Togo K, et al. Patterns of drug treatment in patients with osteoarthritis and chronic low back pain in Japan: a retrospective database study. J Pain Res. 2019;12:1631–1648.
   PubMed Web of Science ®Google Scholar
• Nalamachu SR, Robinson RL, Viktrup L, et al. Multimodal treatment patterns for osteoarthritis and their relationship to patient-reported pain severity: a cross-sectional survey in the United States. J Pain Res. 2020;13:3415–3425.
   PubMed Web of Science ®Google Scholar
• Schnitzer TJ, Marks JA. A systematic review of the efficacy and general safety of antibodies to NGF in the treatment of OA of the hip or knee. Osteoarthritis Cartilage. 2015;23(Suppl 1):S8–17.
   PubMed Web of Science ®Google Scholar
• Yang S, Huang Y, Ye Z, et al. The efficacy of nerve growth factor antibody for the treatment of osteoarthritis pain and chronic low-back pain: a meta-analysis. Front Pharmacol. 2020;11:817.
   PubMed Web of Science ®Google Scholar
• Mayorga AJ, Wang S, Kelly KM, et al. Efficacy and safety of fulranumab as monotherapy in patients with moderate to severe, chronic knee pain of primary osteoarthritis: a randomised, placebo- and active-controlled trial. Int J Clin Pract. 2016;70(6):493–505.
   PubMed Web of Science ®Google Scholar
• Ekman EF, Gimbel JS, Bello AE, et al. Efficacy and safety of intravenous tanezumab for the symptomatic treatment of osteoarthritis: 2 randomized controlled trials versus naproxen. J Rheumatol. 2014;41(11):2249–2259.
   PubMed Web of Science ®Google Scholar
• Spierings EL, Fidelholtz J, Wolfram G, et al. A phase III placebo- and oxycodone-controlled study of tanezumab in adults with osteoarthritis pain of the hip or knee. Pain. 2013;154(9):1603–1612.
   PubMed Web of Science ®Google Scholar
• Schnitzer TJ, Ekman EF, Spierings EL, et al. Efficacy and safety of tanezumab monotherapy or combined with non-steroidal anti-inflammatory drugs in the treatment of knee or hip osteoarthritis pain. Ann Rheum Dis. 2015;74(6):1202–1211.
   PubMed Web of Science ®Google Scholar
• Woller SA, Eddinger KA, Corr M, et al. An overview of pathways encoding nociception. Clin Exp Rheumatol. 2017;35 Suppl 107(Suppl 5):40–46.
   PubMed Web of Science ®Google Scholar
• Garland EL. Pain processing in the human nervous system: a selective review of nociceptive and biobehavioral pathways. Prim Care. 2012;39(3):561–571.
   PubMed Web of Science ®Google Scholar
• Mantyh PW, Koltzenburg M, Mendell LM, et al. Antagonism of nerve growth factor-TrkA signaling and the relief of pain. Anesthesiology. 2011;115(1):189–204.
   PubMed Web of Science ®Google Scholar
• Schmelz M, Mantyh P, Malfait AM, et al. Nerve growth factor antibody for the treatment of osteoarthritis pain and chronic low-back pain: mechanism of action in the context of efficacy and safety. Pain. 2019;160(10):2210–2220.
   PubMed Web of Science ®Google Scholar
• Bushnell MC, Ceko M, Low LA. Cognitive and emotional control of pain and its disruption in chronic pain. Nat Rev Neurosci. 2013;14(7):502–511.
   PubMed Web of Science ®Google Scholar
• Todd AJ. Identifying functional populations among the interneurons in laminae I-III of the spinal dorsal horn. Mol Pain. 2017;13:1744806917693003.
   Web of Science ®Google Scholar
• International Association for the Study of Pain. IASP terminology [Internet]. [updated 2017 Dec 14. cited 2020 Oct 20]. Available from: https://www.iasp-pain.org/terminology
   Google Scholar
• Colloca L, Ludman T, Bouhassira D, et al. Neuropathic pain. Nat Rev Dis Primers. 2017;3(1):17002.
   PubMed Web of Science ®Google Scholar
• Nlm Q, Santin JR, Stoeberl LC, et al. Pharmacological treatment of chemotherapy-induced neuropathic pain: pPARγ agonists as a promising tool. Front Neurosci. 2019;13:907.
   PubMed Web of Science ®Google Scholar
• Schomberg D, Ahmed M, Miranpuri G, et al. Neuropathic pain: role of inflammation, immune response, and ion channel activity in central injury mechanisms. Ann Neurosci. 2012;19(3):125–132.
   PubMedGoogle Scholar
• Stanos S, Brodsky M, Argoff C, et al. Rethinking chronic pain in a primary care setting. Postgrad Med. 2016;128(5):502–515.
   PubMed Web of Science ®Google Scholar
• Xu Q, Yaksh TL. A brief comparison of the pathophysiology of inflammatory versus neuropathic pain. Curr Opin Anaesthesiol. 2011;24(4):400–407.
   PubMed Web of Science ®Google Scholar
• Latremoliere A, Woolf CJ. Central sensitization: a generator of pain hypersensitivity by central neural plasticity. J Pain. 2009;10(9):895–926.
   PubMed Web of Science ®Google Scholar
• Graven-Nielsen T, Arendt-Nielsen L. Peripheral and central sensitization in musculoskeletal pain disorders: an experimental approach. Curr Rheumatol Rep. 2002;4(4):313–321.
   PubMedGoogle Scholar
• Kidd BL, Urban LA. Mechanisms of inflammatory pain. Br J Anaesth. 2001;87(1):3–11.
   PubMed Web of Science ®Google Scholar
• Jimenez-Andrade JM, Mantyh PW. Sensory and sympathetic nerve fibers undergo sprouting and neuroma formation in the painful arthritic joint of geriatric mice. Arthritis Res Ther. 2012;14(3):R101.
   PubMed Web of Science ®Google Scholar
• Chung K, Chung JM. Sympathetic sprouting in the dorsal root ganglion after spinal nerve ligation: evidence of regenerative collateral sprouting. Brain Res. 2001;895(1–2):204–212.
   PubMed Web of Science ®Google Scholar
• Ghilardi JR, Freeman KT, Jimenez-Andrade JM, et al. Neuroplasticity of sensory and sympathetic nerve fibers in a mouse model of a painful arthritic joint. Arthritis Rheum. 2012;64(7):2223–2232.
   PubMed Web of Science ®Google Scholar
• Totsch SK, Sorge RE. Immune system involvement in specific pain conditions. Mol Pain. 2017;13:1744806917724559.
   Web of Science ®Google Scholar
• Schlereth T, Birklein F. The sympathetic nervous system and pain. Neuromolecular Med. 2008;10(3):141–147.
   PubMed Web of Science ®Google Scholar
• Pulvers K, Hood A. The role of positive traits and pain catastrophizing in pain perception. Curr Pain Headache Rep. 2013;17(5):330.
   PubMed Web of Science ®Google Scholar
• Neogi T. The epidemiology and impact of pain in osteoarthritis. Osteoarthritis Cartilage. 2013;21(9):1145–1153.
   PubMed Web of Science ®Google Scholar
• Quartana PJ, Campbell CM, Edwards RR. Pain catastrophizing: a critical review. Expert Rev Neurother. 2009;9(5):745–758.
   PubMed Web of Science ®Google Scholar
• Edwards RR, Smith MT, Kudel I, et al. Pain-related catastrophizing as a risk factor for suicidal ideation in chronic pain. Pain. 2006;126(1):272–279. .
   PubMed Web of Science ®Google Scholar
• Semeru GM, Halim MS. Acceptance versus catastrophizing in predicting quality of life in patients with chronic low back pain. Korean J Pain. 2019;32(1):22–29.
   PubMed Web of Science ®Google Scholar
• Campbell CM, Buenaver LF, Finan P, et al. Sleep, pain catastrophizing, and central sensitization in knee osteoarthritis patients with and without insomnia. Arthritis Care Res (Hoboken). 2015;67(10):1387–1396.
   PubMed Web of Science ®Google Scholar
• McDougall JJ. Arthritis and pain Neurogenic origin of joint pain. Arthritis Res Ther. 2006;8(6):220.
   PubMed Web of Science ®Google Scholar
• Loeser RF, Goldring SR, Scanzello CR, et al. Osteoarthritis: a disease of the joint as an organ. Arthritis Rheum. 2012;64(6):1697–1707.
   PubMed Web of Science ®Google Scholar
• Bedson J, Croft PR. The discordance between clinical and radiographic knee osteoarthritis: a systematic search and summary of the literature. BMC Musculoskelet Disord. 2008;9(1):116.
   PubMed Web of Science ®Google Scholar
• Suokas AK, Walsh DA, McWilliams DF, et al. Quantitative sensory testing in painful osteoarthritis: a systematic review and meta-analysis. Osteoarthritis Cartilage. 2012;20(10):1075–1085.
   PubMed Web of Science ®Google Scholar
• Miller RE, Miller RJ, Malfait A-M. Osteoarthritis joint pain: the cytokine connection. Cytokine. 2014;70(2):185–193.
   PubMed Web of Science ®Google Scholar
• Lluch E, Torres R, Nijs J, et al. Evidence for central sensitization in patients with osteoarthritis pain: a systematic literature review. Eur J Pain. 2014;18(10):1367–1375.
   PubMed Web of Science ®Google Scholar
• Kc R, Li X, Kroin JS, et al. PKCδ null mutations in a mouse model of osteoarthritis alter osteoarthritic pain independently of joint pathology by augmenting NGF/TrkA-induced axonal outgrowth. Ann Rheum Dis. 2016;75(12):2133–2141.
   PubMed Web of Science ®Google Scholar
• Burian M, Geisslinger G. COX-dependent mechanisms involved in the antinociceptive action of NSAIDs at central and peripheral sites. Pharmacol Ther. 2005;107(2):139–154.
   PubMed Web of Science ®Google Scholar
• Kirkby NS, Chan MV, Zaiss AK, et al. Systematic study of constitutive cyclooxygenase-2 expression: role of NF-κB and NFAT transcriptional pathways. Proc Natl Acad Sci U S A. 2016;113(2):434–439.
   PubMed Web of Science ®Google Scholar
• Smyth EM, Grosser T, Wang M, et al. Prostanoids in health and disease. J Lipid Res. 2009;50(Suppl):S423–428.
   PubMed Web of Science ®Google Scholar
• Meves H. The action of prostaglandins on ion channels. Curr Neuropharmacol. 2006;4(1):41–57.
   PubMed Web of Science ®Google Scholar
• Svensson CI, Yaksh TL. THESPINAL P HOSPHOLIPASE-C YCLOOXYGENASE-PROSTANOID CASCADE IN NOCICEPTIVE PROCESSING. Annu Rev Pharmacol Toxicol. 2002;42(1):553–583.
   PubMed Web of Science ®Google Scholar
• Prostaglandin KA. E2 and pain--an update. Biol Pharm Bull. 2011;34(8):1170–1173.
   PubMed Web of Science ®Google Scholar
• Petho G, Reeh PW. Sensory and signaling mechanisms of bradykinin, eicosanoids, platelet-activating factor, and nitric oxide in peripheral nociceptors. Physiol Rev. 2012;92(4):1699–1775.
   PubMed Web of Science ®Google Scholar
• Vanegas H, Vazquez E, Tortorici V. NSAIDs, opioids, cannabinoids and the control of pain by the central nervous system. Pharmaceuticals (Basel). 2010;3(5):1335–1347.
   PubMedGoogle Scholar
• Li X, Ellman M, Muddasani P, et al. Prostaglandin E2 and its cognate EP receptors control human adult articular cartilage homeostasis and are linked to the pathophysiology of osteoarthritis. Arthritis Rheum. 2009;60(2):513–523.
   PubMed Web of Science ®Google Scholar
• Tu M, Yang M, Yu N, et al. Inhibition of cyclooxygenase-2 activity in subchondral bone modifies a subtype of osteoarthritis. Bone Res. 2019;7(1):29.
   PubMed Web of Science ®Google Scholar
• Bannuru RR, Osani MC, Vaysbrot EE, et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage. 2019;27(11):1578–1589.
   PubMed Web of Science ®Google Scholar
• Da Costa BR, Reichenbach S, Keller N, et al. Effectiveness of non-steroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network meta-analysis. Lancet. 2017;390(10090):e21–33.
   PubMed Web of Science ®Google Scholar
• Bannuru RR, Schmid CH, Kent DM, et al. Comparative effectiveness of pharmacologic interventions for knee osteoarthritis: a systematic review and network meta-analysis. Ann Intern Med. 2015;162(1):46–54.
   PubMed Web of Science ®Google Scholar
• Osani MC, Vaysbrot EE, Zhou M, et al. Duration of symptom relief and early trajectory of adverse events for oral nonsteroidal antiinflammatory drugs in knee osteoarthritis: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2020;72(5):641–651.
   PubMed Web of Science ®Google Scholar
• Ton J, Perry D, Thomas B, et al. PEER umbrella systematic review of systematic reviews: management of osteoarthritis in primary care. Can Fam Physician. 2020;66(3):e89–98.
   PubMed Web of Science ®Google Scholar
• Wongrakpanich S, Wongrakpanich A, Melhado K, et al. A comprehensive review of non-steroidal anti-inflammatory drug use in the elderly. Aging Dis. 2018;9(1):143–150.
   PubMed Web of Science ®Google Scholar
• CELEBREX® (celecoxib) US prescribing information [Internet]. New York, NY: Pfizer Inc. [updated 2018 June; cited 2020 Oct 21]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020998s050lbl.pdf
   Google Scholar
• Voltaren® (diclofenac sodium enteric-coated tablets) US prescribing information [Internet]. Parsippany, NJ: novartis Consumer Health, Inc. [updated 2011 Feb; cited 2020 Oct 21]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019201s039s040lbl.pdf
   Google Scholar
• Voltaren® gel (diclofenac sodium topical gel) US prescribing information [Internet] . Parsippany, NJ: novartis Consumer Health, Inc. [updated 2009 July. cited 2020 Oct 21]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022122s006lbl.pdf
   Google Scholar
• Sostres C, Gargallo CJ, Lanas A. Nonsteroidal anti-inflammatory drugs and upper and lower gastrointestinal mucosal damage. Arthritis Res Ther. 2013;15(Suppl 3):S3.
   PubMed Web of Science ®Google Scholar
• Honvo G, Leclercq V, Geerinck A, et al. Safety of topical non-steroidal anti-inflammatory drugs in osteoarthritis: outcomes of a systematic review and meta-analysis. Drugs Aging. 2019;36(Suppl S1):45–64.
   PubMed Web of Science ®Google Scholar
• Przybyła GW, Szychowski KA, Paracetamol GJ. An old drug with new mechanisms of action. Clin Exp Pharmacol Physiol. 2021;48(1):3–19.
   PubMed Web of Science ®Google Scholar
• Mallet C, Daulhac L, Bonnefont J, et al. Endocannabinoid and serotonergic systems are needed for acetaminophen-induced analgesia. Pain. 2008;139(1):190–200.
   PubMed Web of Science ®Google Scholar
• Klinger-Gratz PP, Ralvenius WT, Neumann E, et al. Acetaminophen relieves inflammatory pain through CB(1) cannabinoid receptors in the rostral ventromedial medulla. J Neurosci. 2018;38(2):322–334.
   PubMed Web of Science ®Google Scholar
• Giuffrida A, Beltramo M, Piomelli D. Mechanisms of endocannabinoid inactivation: biochemistry and pharmacology. J Pharmacol Exp Ther. 2001;298(1):7–14.
   PubMed Web of Science ®Google Scholar
• Glaser ST, Kaczocha M. Cyclooxygenase-2 mediates anandamide metabolism in the mouse brain. J Pharmacol Exp Ther. 2010;335(2):380–388.
   PubMed Web of Science ®Google Scholar
• Kerckhove N, Mallet C, François A, et al. Ca(v)3.2 calcium channels: the key protagonist in the supraspinal effect of paracetamol. Pain. 2014;155(4):764–772.
   PubMed Web of Science ®Google Scholar
• Ray S, Salzer I, Kronschläger MT, et al. The paracetamol metabolite N-acetylp-benzoquinone imine reduces excitability in first- and second-order neurons of the pain pathway through actions on KV7 channels. Pain. 2019;160(4):954–964.
   PubMed Web of Science ®Google Scholar
• Machado GC, Maher CG, Ferreira PH, et al. Efficacy and safety of paracetamol for spinal pain and osteoarthritis: systematic review and meta-analysis of randomised placebo controlled trials. BMJ. 2015;350(mar31 2):h1225.
   PubMed Web of Science ®Google Scholar
• Towheed TE, Maxwell L, Judd MG, et al. Acetaminophen for osteoarthritis. Cochrane Database Syst Rev. 2006; (1):CD004257. DOI:https://doi.org/10.1002/14651858.CD004257.pub2.
   PubMed Web of Science ®Google Scholar
• Conaghan PG, Arden N, Avouac B, et al. Safety of paracetamol in osteoarthritis: what does the literature say? Drugs Aging. 2019;36(Suppl S1):7–14.
   PubMed Web of Science ®Google Scholar
• Yoon E, Babar A, Choudhary M, et al. Acetaminophen-induced hepatotoxicity: a comprehensive update. J Clin Transl Hepatol. 2016;4(2):131–142.
   PubMed Web of Science ®Google Scholar
• Ramachandran A, Jaeschke H. Mechanisms of acetaminophen hepatotoxicity and their translation to the human pathophysiology. J Clin Trans Res. 2017;3(Suppl 1):157–169.
   Google Scholar
• Al-Hasani R, Bruchas Michael R. Molecular mechanisms of opioid receptor-dependent signaling and behavior. Anesthesiology. 2011;115(6):1363–1381.
   PubMed Web of Science ®Google Scholar
• McDonald J, Lambert D. Opioid receptors. BJA Educ. 2014;15(5):219–224.
   Web of Science ®Google Scholar
• Yaksh TL. Pharmacology and mechanisms of opioid analgesic activity. Acta Anaesthesiol Scand. 1997;41(1):94–111.
   PubMed Web of Science ®Google Scholar
• Yaksh TL, Fisher CJ, Hockman TM, et al. Current and future issues in the development of spinal agents for the management of pain. Curr Neuropharmacol. 2017;15(2):232–259.
   PubMed Web of Science ®Google Scholar
• Zubieta J-K, Ketter TA, Bueller JA, et al. Regulation of human affective responses by anterior cingulate and limbic µ-opioid neurotransmission. Arch Gen Psychiatry. 2003;60(11):1145–1153.
   PubMed Web of Science ®Google Scholar
• Iwaszkiewicz KS, Schneider JJ, Hua S. Targeting peripheral opioid receptors to promote analgesic and anti-inflammatory actions. Front Pharmacol. 2013;4:132.
   PubMed Web of Science ®Google Scholar
• Stein C, Lang LJ. Peripheral mechanisms of opioid analgesia. Curr Opin Pharmacol. 2009;9(1):3–8.
   PubMed Web of Science ®Google Scholar
• Da Costa BR, Nüesch E, Kasteler R, et al. Oral or transdermal opioids for osteoarthritis of the knee or hip. Cochrane Database Syst Rev. 2014(9):CD003115
   PubMed Web of Science ®Google Scholar
• Osani MC, Lohmander LS, Bannuru RR. Is there any role for opioids in the management of knee and hip osteoarthritis? A systematic review and meta-analysis. In Arthritis Care Res (Hoboken). 2020.
   Google Scholar
• Welsch P, Petzke F, Klose P, et al. Opioids for chronic osteoarthritis pain: an updated systematic review and meta-analysis of efficacy, tolerability and safety in randomized placebo-controlled studies of at least 4 weeks double-blind duration. Eur J Pain. 2020;24(4):685–703.
   PubMed Web of Science ®Google Scholar
• Tramadol hydrochloride US prescribing information [Internet]. [updated 2010 May; cited 2020 Oct 21]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022370s000lbl.pdf
   Google Scholar
• DILAUDID® (hydromorphone hydrochloride) US prescribing information [Internet]. Stamford, CT: purdue Pharma L.P. [updated 2016 Dec. cited 2020 Oct 21]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/019891s024%2C019892s029lbl.pdf
   Google Scholar
• OXYCONTIN® (oxycodone hydrochloride) US prescribing information [Internet]. Stamford, CT: purdue Pharma L.P. [updated 2015 Aug cited 2020 Oct 21]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022272s027lbl.pdf
   Google Scholar
• Galligan JJ, Akbarali HI. Molecular physiology of enteric opioid receptors. Am J Gastroenterol Suppl. 2014;2(1):17–21.
   PubMedGoogle Scholar
• Smith HS, Laufer A. Opioid induced nausea and vomiting. Eur J Pharmacol. 2014;722:67–78.
   PubMed Web of Science ®Google Scholar
• Pattinson KT. Opioids and the control of respiration. Br J Anaesth. 2008;100(6):747–758.
   PubMed Web of Science ®Google Scholar
• Kosten TR, George TP. The neurobiology of opioid dependence: implications for treatment. Sci Pract Perspect. 2002;1(1):13–20.
   PubMedGoogle Scholar
• Vowles KE, McEntee ML, Julnes PS, et al. Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis. Pain. 2015;156(4):569–576.
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human Services. What is the U.S. opioid epidemic? [Internet]. 2019 [updated 2020 Sept 2019; cited 2020 Oct 20]. Available from: https://www.hhs.gov/opioids/about-the-epidemic/
   Google Scholar
• Colvin LA, Bull F, Hales TG. Perioperative opioid analgesia-when is enough too much? A review of opioid-induced tolerance and hyperalgesia. Lancet. 2019;393(10180):1558–1568.
   PubMed Web of Science ®Google Scholar
• Barker PA, Mantyh P, Arendt-Nielsen L, et al. Nerve Growth Factor Signaling and Its Contribution to Pain. J Pain Res. 2020;13:1223–1241.
   PubMed Web of Science ®Google Scholar
• Aloe L, Rocco ML, Balzamino BO, et al. Nerve growth factor: a focus on neuroscience and therapy. Curr Neuropharmacol. 2015;13(3):294–303.
   PubMed Web of Science ®Google Scholar
• Petty BG, Cornblath DR, Adornato BT, et al. The effect of systemically administered recombinant human nerve growth factor in healthy human subjects. Ann Neurol. 1994;36(2):244–246.
   PubMed Web of Science ®Google Scholar
• Rukwied R, Mayer A, Kluschina O, et al. NGF induces non-inflammatory localized and lasting mechanical and thermal hypersensitivity in human skin. Pain. 2010;148(3):407–413.
   PubMed Web of Science ®Google Scholar
• Andresen T, Nilsson M, Nielsen AK, et al. Intradermal injection with nerve growth factor: a reproducible model to induce experimental allodynia and hyperalgesia. Pain Pract. 2016;16(1):12–23.
   PubMed Web of Science ®Google Scholar
• Hayashi K, Shiozawa S, Ozaki N, et al. Repeated intramuscular injections of nerve growth factor induced progressive muscle hyperalgesia, facilitated temporal summation, and expanded pain areas. Pain. 2013;154(11):2344–2352.
   PubMed Web of Science ®Google Scholar
• Minnone G, De Benedetti F. Bracci-Laudiero L. NGF and its receptors in the regulation of inflammatory response. Int J Mol Sci. 2017;18(5):1028.
   PubMed Web of Science ®Google Scholar
• Marlin MC, Li G. Biogenesis and function of the NGF/TrkA signaling endosome. Int Rev Cell Mol Biol. 2015;314:239–257.
   PubMed Web of Science ®Google Scholar
• Stoppiello LA, Mapp PI, Wilson D, et al. Structural associations of symptomatic knee osteoarthritis. Arthritis Rheumatol. 2014;66(11):3018–3027.
   PubMed Web of Science ®Google Scholar
• Pecchi E, Priam S, Gosset M, et al. Induction of nerve growth factor expression and release by mechanical and inflammatory stimuli in chondrocytes: possible involvement in osteoarthritis pain. Arthritis Res Ther. 2014;16(1):R16.
   PubMed Web of Science ®Google Scholar
• Manni L, Lundeberg T, Fiorito S, et al. Nerve growth factor release by human synovial fibroblasts prior to and following exposure to tumor necrosis factor-alpha, interleukin-1 beta and cholecystokinin-8: the possible role of NGF in the inflammatory response. Clin Exp Rheumatol. 2003;21(5):617–624.
   PubMed Web of Science ®Google Scholar
• Schnitzer TJ, Easton R, Pang S, et al. Effect of tanezumab on joint pain, physical function, and patient global assessment of osteoarthritis among patients with osteoarthritis of the hip or knee: a randomized clinical trial. JAMA. 2019;322(1):37–48.
   PubMed Web of Science ®Google Scholar
• Berenbaum F, Blanco FJ, Guermazi A, et al. Subcutaneous tanezumab for osteoarthritis of the hip or knee: efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period. Ann Rheum Dis. 2020;79(6):800–810.
   PubMed Web of Science ®Google Scholar
• Dakin P, DiMartino SJ, Gao H, et al. The efficacy, tolerability, and joint safety of fasinumab in osteoarthritis pain: a phase IIb/III double-blind, placebo-controlled, randomized clinical trial. Arthritis Rheumatol. 2019;71(11):1824–1834.
   PubMed Web of Science ®Google Scholar
• Kelly KM, Sanga P, Zaki N, et al. Safety and efficacy of fulranumab in osteoarthritis of the hip and knee: results from four early terminated phase III randomized studies. Curr Med Res Opin. 2019;35(12):2117–2127.
   PubMed Web of Science ®Google Scholar
• Hochberg MC, CJ A, TJ S, et al. Long-term safety and efficacy of subcutaneous tanezumab versus nonsteroidal antiinflammatory drugs for hip or knee osteoarthritis: a randomized trial. Arthritis Rheumatol. 2021 [In Press].
   Google Scholar
• Hochberg MC. Serious joint-related adverse events in randomized controlled trials of anti-nerve growth factor monoclonal antibodies. Osteoarthritis Cartilage. 2015;23(Suppl 1):S18–21.
   PubMed Web of Science ®Google Scholar
• Brown M, Koltzenburg M, Nguyen H, et al. Tanezumab does not cause sympathetic nervous system dysfunction in clinical osteoarthritis studies (P3.303). Neurology. 2015;84(Suppl14):3.303.
   Google Scholar
• Belanger P, Butler P, Butt M, et al. From the cover: evaluation of the effects of tanezumab, a monoclonal antibody against nerve growth factor, on the sympathetic nervous system in adult cynomolgus monkeys (Macaca fascicularis): a stereologic, histomorphologic, and cardio functional assessment. Toxicol Sci. 2017;158(2):319–333.
   PubMed Web of Science ®Google Scholar
• Berenbaum F, Schnitzer TJ, Kivitz AJ, et al. General Safety and Tolerability of Subcutaneous Tanezumab for Osteoarthritis: A Pooled Analysis of 3 Randomized, Placebo-Controlled Trials. 2021 May 10. doi:https://doi.org/10.1002/acr.24637
   Google Scholar
• Bannwarth B, Kostine M. Nerve growth factor antagonists: is the future of monoclonal antibodies becoming clearer? Drugs. 2017;77(13):1377–1387.
   PubMed Web of Science ®Google Scholar
• Miller CG, Guermazi A, Roemer F. The current status of imaging in anti-NGF clinical trials. Osteoarthritis Cartilage. 2015;23(Suppl 1):S3–7.
   PubMed Web of Science ®Google Scholar
• Gropp KE, Carlson CS, Evans MG, et al. Effects of monoclonal antibodies against nerve growth factor on healthy bone and joint tissues in mice, rats, and monkeys: histopathologic, biomarker, and microcomputed tomographic assessments. Toxicol Pathol. 2018;46(4):408–420.
   PubMed Web of Science ®Google Scholar
• LaBranche TP, Bendele AM, Omura BC, et al. Nerve growth factor inhibition with tanezumab influences weight-bearing and subsequent cartilage damage in the rat medial meniscal tear model. Ann Rheum Dis. 2017;76(1):295–302 .
   PubMed Web of Science ®Google Scholar
• Hochberg MC, Tive LA, Abramson SB, et al. When is osteonecrosis not osteonecrosis? Adjudication of reported serious adverse joint events in the tanezumab clinical development program. Arthritis Rheumatol. 2016;68(2):382–391.
   PubMed Web of Science ®Google Scholar
• Ayhan E, Kesmezacar H, Akgun I. Intraarticular injections (corticosteroid, hyaluronic acid, platelet rich plasma) for the knee osteoarthritis. World J Orthop. 2014;5(3):351–361.
   PubMedGoogle Scholar
• Kompel AJ, Roemer FW, Murakami AM, et al. Intra-articular Corticosteroid Injections in the Hip and Knee: perhaps Not as Safe as We Thought? Radiology. 2019;293(3):656–663.
   PubMed Web of Science ®Google Scholar
• Altman RD, Manjoo A, Fierlinger A, et al. The mechanism of action for hyaluronic acid treatment in the osteoarthritic knee: a systematic review. BMC Musculoskelet Disord. 2015;16(1):321.
   PubMed Web of Science ®Google Scholar
• CYMBALTA® (duloxetine) US Prescribing Information [Internet] . [ cited 2021 June 7]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021427s052lbl.pdf
   Google Scholar
• Weng C, Xu J, Wang Q, et al. Efficacy and safety of duloxetine in osteoarthritis or chronic low back pain: a Systematic review and meta-analysis. Osteoarthritis Cartilage. 2020;28(6):721–734.
   PubMed Web of Science ®Google Scholar
• Grässel S, Muschter D Recent advances in the treatment of osteoarthritis. F1000Res. 2020;9:F1000 Faculty Rev-1325.
   Google Scholar
• Latourte A, Kloppenburg M, Richette P. Emerging pharmaceutical therapies for osteoarthritis. Nat Rev Rheumatol. 2020;16(12):673–688.
   PubMed Web of Science ®Google Scholar